Aging increases the susceptibility of cisplatin-induced nephrotoxicity

[1]  N. Sutandyo,et al.  Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[2]  Yu-hui Wei,et al.  Role of age-related decrease of renal organic cation transporter 2 in the effect of atenolol on renal excretion of metformin in rats , 2015, European Journal of Drug Metabolism and Pharmacokinetics.

[3]  A. Zwinderman,et al.  The effect of age on the systemic inflammatory response in patients with community-acquired pneumonia. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  C. Edelstein,et al.  Pathophysiology of Cisplatin-Induced Acute Kidney Injury , 2014, BioMed research international.

[5]  B. Buckley,et al.  Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. , 2014, The American journal of pathology.

[6]  S. Ohdo,et al.  Renal Circadian Clock Regulates the Dosing-Time Dependency of Cisplatin-Induced Nephrotoxicity in Mice , 2014, Molecular Pharmacology.

[7]  J. Polli,et al.  Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). , 2013, Toxicology and applied pharmacology.

[8]  A. Gibson,et al.  Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance , 2013, Clinical pharmacology and therapeutics.

[9]  S. Odelberg,et al.  Impaired Transcriptional Activity of Nrf2 in Age-Related Myocardial Oxidative Stress Is Reversible by Moderate Exercise Training , 2012, PloS one.

[10]  R. Westendorp,et al.  The effect of chronological age on the inflammatory response of human fibroblasts , 2012, Experimental Gerontology.

[11]  K. Engelhard,et al.  Influence of Age on Brain Edema Formation, Secondary Brain Damage and Inflammatory Response after Brain Trauma in Mice , 2012, PloS one.

[12]  Jing Zhang,et al.  Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  A. Sparreboom,et al.  Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy , 2012, Clinical pharmacology and therapeutics.

[14]  Minoru Yoshida,et al.  Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events , 2012, Clinical and Experimental Nephrology.

[15]  J. Brockmöller,et al.  Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. , 2011, Pharmacogenomics.

[16]  B. Fromenty,et al.  Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. , 2011, Rejuvenation research.

[17]  A. Yonezawa,et al.  Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. , 2010, Biochemical pharmacology.

[18]  J. Thomale,et al.  Transcriptional Regulation of Renal Cytoprotective Genes by Nrf2 and Its Potential Use as a Therapeutic Target to Mitigate Cisplatin-Induced Nephrotoxicity , 2010, Journal of Pharmacology and Experimental Therapeutics.

[19]  S. Pettit,et al.  Evaluation of Novel Biomarkers of Nephrotoxicity in Two Strains of Rat Treated with Cisplatin , 2010, Toxicologic pathology.

[20]  R. Franke,et al.  Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase , 2010, Clinical Cancer Research.

[21]  Franco J. Vizeacoumar,et al.  Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis , 2010, The Journal of cell biology.

[22]  S. Masuda,et al.  Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. , 2009, Biochemical pharmacology.

[23]  R. Murphy,et al.  The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. , 2009, American journal of physiology. Renal physiology.

[24]  H. Badran,et al.  Age-Related Alteration of Risk Profile, Inflammatory Response, and Angiographic Findings in Patients with Acute Coronary Syndrome , 2009, Clinical medicine. Cardiology.

[25]  Z. Dong,et al.  Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. , 2008, Kidney international.

[26]  S. Akira,et al.  TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. , 2008, Journal of the American Society of Nephrology : JASN.

[27]  R. Zager,et al.  Toll-like receptor (TLR4) shedding and depletion: acute proximal tubular cell responses to hypoxic and toxic injury. , 2007, American journal of physiology. Renal physiology.

[28]  L. Moscetti,et al.  Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome , 2005, Journal of chemotherapy.

[29]  K. Mori,et al.  Neutrophil Gelatinase-Associated Lipocalin: A Novel Early Urinary Biomarker for Cisplatin Nephrotoxicity , 2004, American Journal of Nephrology.

[30]  H. Anders,et al.  Signaling danger: toll-like receptors and their potential roles in kidney disease. , 2004, Journal of the American Society of Nephrology : JASN.

[31]  A. Argiris,et al.  Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. DiPietro,et al.  Age-related alterations in the inflammatory response to dermal injury. , 2001, The Journal of investigative dermatology.

[33]  E. Espinosa,et al.  Renal Tolerance to Cisplatin in Patients 70 Years and Older , 2001, American journal of clinical oncology.

[34]  Student.  Age , 1989, BMJ : British Medical Journal.

[35]  D. Platt,et al.  Age-Dependent Changes of the Kidneys: Pharmacological Implications , 1999, Gerontology.

[36]  O. Sugita.  [Urinary N-acetyl-beta-D-glucosaminidase]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.

[37]  B. Brenner,et al.  Effects of aging on the renal glomerulus. , 1986, The American journal of medicine.

[38]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin , 1986, Clinical pharmacology and therapeutics.

[39]  P. Loehrer,et al.  Drugs five years later. Cisplatin. , 1984, Annals of internal medicine.

[40]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. , 1984, Cancer treatment reports.

[41]  W. Evans,et al.  Clinical pharmacology of bleomycin and cisplatin. , 1981, Drug intelligence & clinical pharmacy.